| NCT ID | NCT04288674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Cologne |
| Condition | Leptospirosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-03-04 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-03-04 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease.
Eligibility Criteria
Inclusion Criteria: * Cultural, serological, molecular or histological evidence of invasive leptospirosis diseases * Clinical signs of disseminated leptospirosis disease without cultural, serological, molecular or histological evidence * Case controls: Matching procedures for controls: Particularly, case controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital). Exclusion Criteria: * Colonization or other non-invasive infection * Cultural, serological, molecular or histological evidence without dissemination
Contact & Investigator
Volker Burst, MD
STUDY CHAIR
University Hospital of Cologne
Frequently Asked Questions
Who can join the NCT04288674 clinical trial?
This trial is open to participants of all sexes, studying Leptospirosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04288674 currently recruiting?
Yes, NCT04288674 is actively recruiting participants. Contact the research team at felix.koehler@uk-koeln.de for enrollment information.
Where is the NCT04288674 trial being conducted?
This trial is being conducted at Cologne, Germany.
Who is sponsoring the NCT04288674 clinical trial?
NCT04288674 is sponsored by University of Cologne. The principal investigator is Volker Burst, MD at University Hospital of Cologne. The trial plans to enroll 200 participants.